X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (151) 151
humans (129) 129
discontinuation (122) 122
oncology (115) 115
chronic myeloid leukemia (102) 102
hematology (100) 100
imatinib (95) 95
chronic myelogenous leukemia (80) 80
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (74) 74
female (73) 73
protein kinase inhibitors - therapeutic use (69) 69
male (68) 68
tyrosine (65) 65
tyrosine kinase inhibitors (62) 62
therapy (61) 61
antineoplastic agents - therapeutic use (60) 60
leukemia (57) 57
middle aged (55) 55
dasatinib (51) 51
aged (48) 48
chronic myeloid-leukemia (48) 48
adult (47) 47
cancer (42) 42
care and treatment (42) 42
treatment-free remission (42) 42
treatment outcome (40) 40
cml patients (38) 38
nilotinib (38) 38
complete molecular remission (37) 37
patients (37) 37
cml (36) 36
myeloid leukemia (36) 36
protein-tyrosine kinase (36) 36
remission (36) 36
tyrosine kinase inhibitor (35) 35
follow-up (34) 34
analysis (27) 27
hematology, oncology and palliative medicine (27) 27
leukemia, myelogenous, chronic, bcr-abl positive - genetics (27) 27
clinical trials (26) 26
hemic and lymphatic diseases (26) 26
aged, 80 and over (25) 25
fusion proteins, bcr-abl - genetics (25) 25
imatinib mesylate (25) 25
antineoplastic agents (24) 24
protein kinase inhibitors - administration & dosage (24) 24
remission induction (24) 24
antimitotic agents (23) 23
leukemia, myelogenous, chronic, bcr-abl positive - pathology (23) 23
pyrimidines - therapeutic use (23) 23
interferon-alpha (22) 22
medicine & public health (22) 22
trial (22) 22
chronic-phase (21) 21
deep molecular response (21) 21
imatinib discontinuation (21) 21
molecular response (21) 21
protein kinase inhibitors - adverse effects (21) 21
phenols (20) 20
young adult (20) 20
management (19) 19
survival (19) 19
interferon (18) 18
protein-tyrosine kinases - antagonists & inhibitors (18) 18
antineoplastic agents - administration & dosage (17) 17
imatinib mesylate - therapeutic use (17) 17
prognosis (17) 17
stem cells (17) 17
treatment discontinuation (17) 17
chronic myeloid leukaemia (16) 16
fusion proteins, bcr-abl - antagonists & inhibitors (16) 16
gefitinib (16) 16
quality of life (16) 16
research (16) 16
acquired-resistance (15) 15
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (15) 15
leukemia, myelogenous, chronic, bcr-abl positive - mortality (15) 15
piperazines - therapeutic use (15) 15
protein kinase inhibitors - pharmacology (15) 15
time factors (15) 15
diagnosed chronic-phase (14) 14
erlotinib (14) 14
genetic aspects (14) 14
medical research (14) 14
retrospective studies (14) 14
adolescent (13) 13
antineoplastic agents - adverse effects (13) 13
article (13) 13
bcr-abl (13) 13
chemotherapy (13) 13
disease (13) 13
immunology (13) 13
lung neoplasms - drug therapy (13) 13
medical colleges (13) 13
mutation (13) 13
outcomes (13) 13
pregnancy (13) 13
resistance (13) 13
stem-cells (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Wang, P and Zhang, D and Li, XM and Guo, XG and Sun, BJ and Fang, XQ and Qu, GP and An, L and Liu, CT
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, ISSN 1128-3602, 06/2016, Volume 20, Issue 11, pp. 2450 - 2459
OBJECTIVE: Continued EGFR-TKIs treatment is still controversial for NSCLC patients with activating EGFR mutations, who acquire resistance to the drug. Of these... 
1ST-LINE TREATMENT | Non-dramatic progression | GEFITINIB | Continued EGFR-TKIs | NSCLC | OPEN-LABEL | Elderly patients | CHEMOTHERAPY | DISCONTINUATION | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | TRIAL | DISEASE | PHARMACOLOGY & PHARMACY | ERLOTINIB | Progressive disease
Journal Article
Anticancer Research, ISSN 0250-7005, 08/2018, Volume 38, Issue 8, pp. 4699 - 4704
Background/Aim: Promising reports have described the combination of first-generation epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs)... 
EGFR mutation | Carboplatin | Non-small-cell lung cancer | Afatinib | Pemetrexed | pemetrexed | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | CHEMOTHERAPY | DISCONTINUATION | CELL LUNG-CANCER | TRIAL | ONCOLOGY | carboplatin | MUTATIONS | ERLOTINIB | non-small-cell lung cancer | Index Medicus
Journal Article
Journal Article
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 10/2018, Volume 23, Issue 5, pp. 974 - 979
Journal Article
Lung Cancer, ISSN 0169-5002, 2015, Volume 90, Issue 3, pp. 477 - 483
Journal Article
Cancer, ISSN 0008-543X, 07/2017, Volume 123, Issue 13, pp. 2482 - 2488
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 04/2018, Volume 18, Issue 1, pp. 359 - 8
Journal Article
Nature Medicine, ISSN 1078-8956, 10/2017, Volume 23, Issue 10, pp. 1234 - 1240
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs)... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | KINASE-ACTIVITY | COMPLETE MOLECULAR REMISSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | DISCONTINUATION | CELL BIOLOGY | BCR | METABOLISM | FATTY-ACID OXIDATION | IMATINIB | SUPPORTING ASPARTATE BIOSYNTHESIS | DIFFERENTIATION | Metabolomics | Up-Regulation | Minocycline - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Minocycline - analogs & derivatives | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Oxidative Phosphorylation - drug effects | Imatinib Mesylate - therapeutic use | Neoplastic Stem Cells - metabolism | Mass Spectrometry | Chromatography, Liquid | Female | Tumor Cells, Cultured | Drug Therapy, Combination | Cell Survival - drug effects | Tumor Stem Cell Assay | Imatinib Mesylate - pharmacology | Mitochondria - metabolism | Mitochondria - drug effects | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Phenformin - pharmacology | Hypoglycemic Agents - pharmacology | Xenograft Model Antitumor Assays | Animals | Protein Kinase Inhibitors - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice, Inbred NOD | Anti-Bacterial Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | In Vitro Techniques | Drug Resistance, Neoplasm - drug effects | Oxidative stress | Care and treatment | Genotype | Development and progression | Genetic aspects | Chronic myeloid leukemia | Health aspects | Phosphorylation | Transformation | Target recognition | Oxidative metabolism | Leukemia | Xenotransplantation | Disease resistance | Oxidation resistance | Mitochondria | Transformed cells | CD38 antigen | Xenografts | Drug therapy | Protein-tyrosine kinase | Chronic illnesses | Tyrosine | CD34 antigen | Imatinib | Cell survival | Myeloid leukemia | Minimal residual disease | Metabolism | Survival | Oxidative phosphorylation | Antibiotics | Stem cells | Tigecycline
Journal Article